FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170408035> ?p ?o ?g. }

• W2170408035 endingPage "624" @default.
• W2170408035 startingPage "619" @default.
• W2170408035 abstract "High-dose busulfan is widely used in allogeneic and autologous marrow transplantation preparative regimens. Variation in the area under the concentration/time curve (AUC) for oral busulfan results in substantial risk of over or under treatment with excess risk of toxicity or relapse. Use of the IV formulation reduces this variability by eliminating variability in absorption. Variability due to drug metabolism remains, but simplified pharmacokinetic study may be employed to achieve a specific target AUC. In conventional sampling strategies for determining AUC after oral administration, 12 samples are used over 6 hours to assure accurate tracking of erratic absorption. With IV busulfan there is no necessity for measuring plasma levels during the infusion because busulfan pharmacokinetics are well described with a single-compartment, first-order elimination model. In theory, only peak and trough levels should be necessary, but for assurance of reliability in clinical decision making, it must be possible to identify outlier values. This process requires at least 4 samples. We studied a total of 59 adult patients receiving a 2-hour IV busulfan infusion to develop a limited sampling strategy (LSS). At the end of a 2-hour infusion, we collected 11 samples from 18 patients and compared the AUC obtained when all samples were used with the AUC obtained when samples were collected only hourly. The mean AUC calculation was 5% higher (1002 versus 956 microM-min) and the coefficient of variation (CV) was substantially better (4.6% versus 8.2%) when only the postinfusion samples were used. A follow-up study of 41 consecutive patients demonstrated that all patients were easily evaluable with a coefficient of variation (CV) for the AUC of 2.6%. To validate this approach, we analyzed pharmacokinetic data on 60 patients in the phase II clinical trial of the IV formulation described by Anderson et al. Data on an additional 36 patients from a companion study also were analyzed. The AUC based on all 11 samples from each patient were compared with the AUC based on the 5 postinfusion samples. The results of this analysis confirmed comparable reliability and possibly superior precision of the University of Alabama at Birmingham 5-sample LSS. These results validated that LSS for IV busulfan will make possible meaningful and accurate comparisons of busulfan versus TBI-based preparative regimens and comparison of dose intensity of busulfan-containing preparative regimens in trials of submyeloablative transplantation." @default.
• W2170408035 created "2016-06-24" @default.
• W2170408035 creator A5005124841 @default.
• W2170408035 creator A5006636719 @default.
• W2170408035 creator A5017045908 @default.
• W2170408035 creator A5051641118 @default.
• W2170408035 creator A5052633473 @default.
• W2170408035 date "2002-11-01" @default.
• W2170408035 modified "2023-10-03" @default.
• W2170408035 title "A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan" @default.
• W2170408035 cites W1487950379 @default.
• W2170408035 cites W1519928058 @default.
• W2170408035 cites W1565345042 @default.
• W2170408035 cites W169590802 @default.
• W2170408035 cites W1972172571 @default.
• W2170408035 cites W1997472326 @default.
• W2170408035 cites W2004308189 @default.
• W2170408035 cites W2019025531 @default.
• W2170408035 cites W2038424578 @default.
• W2170408035 cites W2067480394 @default.
• W2170408035 cites W2085854997 @default.
• W2170408035 cites W2116478257 @default.
• W2170408035 cites W2153230966 @default.
• W2170408035 cites W2314192225 @default.
• W2170408035 cites W2339482838 @default.
• W2170408035 cites W2411096388 @default.
• W2170408035 cites W2415603966 @default.
• W2170408035 cites W44768847 @default.
• W2170408035 cites W6829174 @default.
• W2170408035 cites W9562913 @default.
• W2170408035 doi "https://doi.org/10.1053/bbmt.2002.v8.abbmt080619" @default.
• W2170408035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12463481" @default.
• W2170408035 hasPublicationYear "2002" @default.
• W2170408035 type Work @default.
• W2170408035 sameAs 2170408035 @default.
• W2170408035 citedByCount "41" @default.
• W2170408035 countsByYear W21704080352012 @default.
• W2170408035 countsByYear W21704080352013 @default.
• W2170408035 countsByYear W21704080352014 @default.
• W2170408035 countsByYear W21704080352015 @default.
• W2170408035 countsByYear W21704080352016 @default.
• W2170408035 countsByYear W21704080352017 @default.
• W2170408035 countsByYear W21704080352018 @default.
• W2170408035 countsByYear W21704080352019 @default.
• W2170408035 countsByYear W21704080352020 @default.
• W2170408035 countsByYear W21704080352021 @default.
• W2170408035 countsByYear W21704080352023 @default.
• W2170408035 crossrefType "journal-article" @default.
• W2170408035 hasAuthorship W2170408035A5005124841 @default.
• W2170408035 hasAuthorship W2170408035A5006636719 @default.
• W2170408035 hasAuthorship W2170408035A5017045908 @default.
• W2170408035 hasAuthorship W2170408035A5051641118 @default.
• W2170408035 hasAuthorship W2170408035A5052633473 @default.
• W2170408035 hasBestOaLocation W21704080351 @default.
• W2170408035 hasConcept C105795698 @default.
• W2170408035 hasConcept C112705442 @default.
• W2170408035 hasConcept C126322002 @default.
• W2170408035 hasConcept C126894567 @default.
• W2170408035 hasConcept C2777408962 @default.
• W2170408035 hasConcept C2780272996 @default.
• W2170408035 hasConcept C2780611847 @default.
• W2170408035 hasConcept C2909675724 @default.
• W2170408035 hasConcept C2911091166 @default.
• W2170408035 hasConcept C31785415 @default.
• W2170408035 hasConcept C33923547 @default.
• W2170408035 hasConcept C71924100 @default.
• W2170408035 hasConcept C76318530 @default.
• W2170408035 hasConcept C89838059 @default.
• W2170408035 hasConcept C98274493 @default.
• W2170408035 hasConceptScore W2170408035C105795698 @default.
• W2170408035 hasConceptScore W2170408035C112705442 @default.
• W2170408035 hasConceptScore W2170408035C126322002 @default.
• W2170408035 hasConceptScore W2170408035C126894567 @default.
• W2170408035 hasConceptScore W2170408035C2777408962 @default.
• W2170408035 hasConceptScore W2170408035C2780272996 @default.
• W2170408035 hasConceptScore W2170408035C2780611847 @default.
• W2170408035 hasConceptScore W2170408035C2909675724 @default.
• W2170408035 hasConceptScore W2170408035C2911091166 @default.
• W2170408035 hasConceptScore W2170408035C31785415 @default.
• W2170408035 hasConceptScore W2170408035C33923547 @default.
• W2170408035 hasConceptScore W2170408035C71924100 @default.
• W2170408035 hasConceptScore W2170408035C76318530 @default.
• W2170408035 hasConceptScore W2170408035C89838059 @default.
• W2170408035 hasConceptScore W2170408035C98274493 @default.
• W2170408035 hasIssue "11" @default.
• W2170408035 hasLocation W21704080351 @default.
• W2170408035 hasLocation W21704080352 @default.
• W2170408035 hasOpenAccess W2170408035 @default.
• W2170408035 hasPrimaryLocation W21704080351 @default.
• W2170408035 hasRelatedWork W1053912254 @default.
• W2170408035 hasRelatedWork W1984291491 @default.
• W2170408035 hasRelatedWork W2011948815 @default.
• W2170408035 hasRelatedWork W2019820056 @default.
• W2170408035 hasRelatedWork W2083019900 @default.
• W2170408035 hasRelatedWork W2092925654 @default.
• W2170408035 hasRelatedWork W2170408035 @default.
• W2170408035 hasRelatedWork W2417615862 @default.
• W2170408035 hasRelatedWork W4245180657 @default.

• next